Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: Application of antigen-specific immune tolerance in autoimmune disease is a long-sought goal. We studied diseases with abundant information on the autoimmune target: in multiple sclerosis (MS), various myelin antigens are known targets of T cells and antibodies, whereas in neuromyelitis optica (NMO), the aquaporin-4 channel is attacked by T cells and antibodies. We tested whether engineered dendritic cells might induce a tolerogenic immune response in these two conditions. In this in-human clinical study, individual regulatory T cells, secreting IL-10, a key tolerogenic cytokine, were detected after treatment. These results might lead to more extensive trials with this approach in autoimmune conditions where the antigenic target has been identified, including MS, NMO, myasthenia gravis, and Graves disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011 · cited 8×
“Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS).”
BackgroundMethodInfluentialDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802 · cited 1×
“Inclusion criteria were (i) patients diagnosed with MS based on the 2010 McDonald criteria (18) or NMOSD with antiAQP4 antibodies based on Wingerchuk criteria (19); (ii) disease duration ≥1 y; (iii) age between 18 and 65 y; and (iv) EDSS between 3 and 8.”
BackgroundInternational consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Ruiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
Fischer, J. S., Rudick, R. A., Cutter, G. R., Reingold, S. C., & National MS Society Clinical Outcomes Assessment Task Force (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500409 · Cited by 993
Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823 · cited 1×
“Considering previous findings reporting reactivation of MS activity after altered ligand peptide therapy (30), it is important to highlight that therapy using tolDCs loaded with myelin peptide was safe.”
BackgroundGregori, S., Tomasoni, D., Pacciani, V., Scirpoli, M., Battaglia, M., Magnani, C. F., Hauben, E., & Roncarolo, M.-G. (2010) · Blood · doi:10.1182/blood-2009-07-234872 · Cited by 561
Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients
Giannoukakis, N., Phillips, B., Finegold, D., Harnaha, J., & Trucco, M. (2011) · Diabetes Care · doi:10.2337/dc11-0472 · Cited by 407
Unger, W. W. J., Laban, S., Kleijwegt, F. S., van der Slik, A. R., & Roep, B. O. (2009) · European Journal of Immunology · doi:10.1002/eji.200839103 · Cited by 395
Benham, H., Nel, H. J., Law, S. C., Mehdi, A. M., Street, S., Ramnoruth, N., Pahau, H., Lee, B. T., Ng, J., G. Brunck, M. E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa9301 · Cited by 379
Varrin‐Doyer, M., Spencer, C. M., Schulze‐Topphoff, U., Nelson, P. A., Stroud, R. M., C. Cree, B. A., & Zamvil, S. S. (2012) · Annals of Neurology · doi:10.1002/ana.23651 · Cited by 341
Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis
Bell, G. M., Anderson, A. E., Diboll, J., Reece, R., Eltherington, O., Harry, R. A., Fouweather, T., MacDonald, C., Chadwick, T., McColl, E., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208456 · Cited by 315
Lutterotti, A., Yousef, S., Sputtek, A., Stürner, K. H., Stellmann, J.-P., Breiden, P., Reinhardt, S., Schulze, C., Bester, M., Heesen, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006168 · Cited by 281
Bielekova, B., Sung, M.-H., Kadom, N., Simon, R., McFarland, H., & Martin, R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3893 · Cited by 241
Jauregui-Amezaga, A., Cabezón, R., Ramírez-Morros, A., España, C., Rimola, J., Bru, C., Pinó-Donnay, S., Gallego, M., Masamunt, M. C., Ordás, I., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv144 · Cited by 167 · cited 4×
“Autologous monocyte-derived dendritic cells (DCs) were obtained by leukapheresis (Amicus; Fresenius Kabi), and tolDCs were generated under good manufacturing practice (GMP) conditions by conditioning monocyte-derived DCs, as previously described (9, 21), and reported following minimum information about tolerogenic ant…”
BackgroundMethodInfluentialSelf-citationIL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis
Martinez‐Forero, I., Garcia‐Munoz, R., Martinez‐Pasamar, S., Inoges, S., Lopez‐Diaz de Cerio, A., Palacios, R., Sepulcre, J., Moreno, B., Gonzalez, Z., Fernandez‐Diez, B., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200737271 · Cited by 142
Self-citationTolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand?
Marín, E., Cuturi, M. C., & Moreau, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00274 · Cited by 123 · cited 2×
“and other stimuli have a stable phenotype, high expression of HLA class II molecules, intermediate expression of the costimulatory molecules CD80 and CD86, low expression of CD40, express high levels of IL-10 and TGF-β, and low levels of IL-12, IL-23, and TNFα, overall conferring a low capacity to stimulate T cells, w…”
BackgroundMERTK as negative regulator of human T cell activation
Cabezón, R., Silva, E. A. C., Flórez‐Grau, G., Errasti, A. E., Calderón‐Gómez, E., Lozano, J. J., a, C. E., Ricart, E., Panés, J., Rothlin, C. V., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0714-334r · Cited by 112 · cited 1×
“S2A, clinical grade-produced tolDCs presented semimature phenotype (lower expression of maturation marker CD83 and MHCII compared with mature DCs) and increased expression of the glucocorticoid-induced receptor MERTK, which was described as a marker for tolDCs (24).”
BackgroundSelf-citationBrussel, I. V., Lee, W. P., Rombouts, M., Nuyts, A. H., Heylen, M., Winter, B. Y. D., Cools, N., & Schrijvers, D. M. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.09.008 · Cited by 111
Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease
Phillips, B. E., Garciafigueroa, Y., Trucco, M., & Giannoukakis, N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01279 · Cited by 106 · cited 1×
“Most of the trials have shown as the main immunological effect an increase in regulatory cells and their related cytokines (10), in agreement with our finding of increased IL-10 production and frequency of Tr1 cells.”
ResultMansilla, M. J., Sellès‐Moreno, C., Fàbregas‐Puig, S., Amoedo, J., Navarro‐Barriuso, J., Teniente‐Serra, A., Grau‐López, L., Ramo-Tello, C. M., & Martínez-Cáceres, E. M. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12342 · Cited by 99 · cited 1×
“injection, and in smaller amounts the lymph nodes, thymus, and bone marrow, and remained stable for 7 d (38).”
BackgroundTolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases
García-González, P. A., Ubilla-Olguín, G., Catalán, D., Schinnerling, K., & Aguillón, J. C. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.032 · Cited by 97
Flórez‐Grau, G., Zubizarreta, I., Cabezón, R., Villoslada, P., & Benítez‐Ribas, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01169 · Cited by 87 · cited 5×
“Considering that the immune system exhibits the remarkable ability to detect sudden increases in the abundance of self-antigens, this model provides a framework for testing antigen-specific tolerance induction based in the exposition of a higher than normal dose of self-antigens [“the 100-fold increase in effective ab…”
BackgroundMethodInfluentialSelf-citationRegulatory dendritic cell therapy: From rodents to clinical application
Regué, D. R., Glancy, M., & Thomson, A. W. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.11.016 · Cited by 75 · cited 2×
“and other stimuli have a stable phenotype, high expression of HLA class II molecules, intermediate expression of the costimulatory molecules CD80 and CD86, low expression of CD40, express high levels of IL-10 and TGF-β, and low levels of IL-12, IL-23, and TNFα, overall conferring a low capacity to stimulate T cells, w…”
BackgroundMethylthioadenosine reverses brain autoimmune disease
Moreno, B., Hevia, H., Santamaria, M., Sepulcre, J., Muñoz, J., García–Trevijano, E. R., Berasain, C., Corrales, F. J., Avila, M. A., & Villoslada, P. (2006) · Annals of Neurology · doi:10.1002/ana.20895 · Cited by 67 · cited 1×
“Measurements were obtained as cpm and calculated the stimulation index (SI) as cpm peptides/cpm unstimulated (26).”
MethodSelf-citationIncreased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica
Matsuya, N., Komori, M., Nomura, K., Nakane, S., Fukudome, T., Goto, H., Shiraishi, H., Wandinger, K.-P., Matsuo, H., & Kondo, T. (2011) · International Immunology · doi:10.1093/intimm/dxr056 · Cited by 57 · cited 1×
“New AQP4 epitopes have been described (44, 45), which would be tested in future trials.”
BackgroundRestoring immune tolerance in neuromyelitis optica: Part II
Bar‐Or, A., Steinman, L., Behne, J. M., Benítez‐Ribas, D., Chin, P. S., Clare-Salzler, M. J., Healey, D. G., Kim, J. I., Kranz, D. M., Lutterotti, A., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000277 · Cited by 57
Self-citationvan Noort, J. M., Bsibsi, M., Nacken, P. J., Verbeek, R., & Venneker, E. H. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143366 · Cited by 56 · cited 1×
“Indeed, tolerance induction with alpha B-crystallin (HspB5) has been tested in patients with MS showing good safety as well (43).”
BackgroundVilloslada, P., Abel, K., Heald, N., Goertsches, R. H., Hauser, S. L., & Genain, C. P. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<2942::aid-immu2942>3.0.co;2-m · Cited by 56
Self-citationLord, P., Spiering, R., Aguillón, J. C., Anderson, A. E., Appel, S., Benítez‐Ribas, D., ten Brinke, A., Broere, F., Cools, N., Cuturi, M. C., et al. (2016) · PeerJ · doi:10.7717/peerj.2300 · Cited by 54
Challenges and opportunities in designing clinical trials for neuromyelitis optica
Weinshenker, B. G., Barron, G., Behne, J. M., Bennett, J. L., Chin, P. S., Cree, B., Seze, J. D., Flor, A., Fujihara, K., Greenberg, B. M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001520 · Cited by 46 · cited 1×
“Excluding criteria were (i) presence of a relapse or use of steroids the month before the screening; (ii) use of immunomodulatory/immunosuppressive therapy in the case of MS in the last 12 mo, but NMOSD patients were allowed to maintain their immunomodulatory treatment stable for 6 mo for ethical requirements (20); (i…”
BackgroundSelf-citationRestoring immune tolerance in neuromyelitis optica: Part I
Steinman, L., Bar‐Or, A., Behne, J. M., Benítez‐Ribas, D., Chin, P. S., Clare-Salzler, M. J., Healey, D. G., Kim, J. I., Kranz, D. M., Lutterotti, A., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000276 · Cited by 43 · cited 2×
“In the case of NMOSD, almost 80% of patients have specific antibodies against AQP4, providing a good target for antigenspecific tolerance-induction strategies (12, 13).”
BackgroundSelf-citationThe multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS
Martínez‐Lapiscina, E. H., Fraga‐Pumar, E., Gabilondo, I., Martínez‐Heras, E., Torres–Torres, R., Ortiz-Pérez, S., Llufriú, S., Tercero-Uribe, A. I., Andorrà, M., Figueras‐Roca, M., et al. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-910 · Cited by 42 · cited 4×
“OCT was performed using a spectral domain device (Spectralis; Heidelberg Engineering), as previously described (14), and performed before therapy initiation and by week 12 follow-up.”
BackgroundMethodInfluentialSelf-citationWang, L., Li, Z., Ćirić, B., Safavi, F., Zhang, G., & Rostami, A. M. (2016) · European Journal of Immunology · doi:10.1002/eji.201546274 · Cited by 41
Norovirus-Specific Memory T Cell Responses in Adult Human Donors
Malm, M., Tamminen, K., Vesikari, T., & Blazevic, V. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01570 · Cited by 39
Predictors of vision impairment in Multiple Sclerosis
Sánchez-Dalmau, B. F., Martínez‐Lapiscina, E. H., Valdeolivas, I. P., Zubizarreta, I., Llufriú, S., Blanco, Y., Solà‐Valls, N., Sepúlveda, M., Guerrero, A., Albà-Arbalat, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195856 · Cited by 33 · cited 1×
“baseline and week 12 following criteria as previously described (25).”
MethodSelf-citationCabezón, R., Ricart, E., España, C., Panés, J., & Benítez‐Ribas, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052456 · Cited by 33 · cited 1×
“Autologous monocyte-derived dendritic cells (DCs) were obtained by leukapheresis (Amicus; Fresenius Kabi), and tolDCs were generated under good manufacturing practice (GMP) conditions by conditioning monocyte-derived DCs, as previously described (9, 21), and reported following minimum information about tolerogenic ant…”
MethodSelf-citationBeyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis
Willekens, B. M. P., & Cools, N. (2018) · CNS Drugs · doi:10.1007/s40263-018-0518-4 · Cited by 29 · cited 1×
“Even if the target antigen remains unknown, by promoting immune tolerogenic responses in adaptive immune cells that migrate to the inflamed CNS, an amelioration of the inflammatory process can be achieved (2).”
BackgroundThe re-emergence of antigen-specific tolerance as a potential therapy for MS
Steinman, L. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515581441 · Cited by 24 · cited 3×
“The search for immune-tolerance therapies or antigen-specific vaccination to treat autoimmune diseases such as MS or NMOSD is based on the need of more selective immunotherapies designed to restore self-tolerance without causing general immune suppression (1).”
BackgroundInfluentialSelf-citationArellano, B., Hussain, R. Z., Zacharias, T., Yoon, J. C., David, C. S., Zein, S., Steinman, L., Forsthuber, T. G., Greenberg, B. M., Lambracht‐Washington, D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1300 · Cited by 20 · cited 1×
“New AQP4 epitopes have been described (44, 45), which would be tested in future trials.”
BackgroundSelf-citationAutoimmunity and tumor immunology: two facets of a probabilistic immune system
Iranzo, J., & Villoslada, P. (2014) · BMC Systems Biology · doi:10.1186/s12918-014-0120-4 · Cited by 10 · cited 3×
“Considering that the immune system exhibits the remarkable ability to detect sudden increases in the abundance of self-antigens, this model provides a framework for testing antigen-specific tolerance induction based in the exposition of a higher than normal dose of self-antigens [“the 100-fold increase in effective ab…”
BackgroundSelf-citationRegulation of fucosyltransferase-VII expression in peripheral lymph node high endothelial venules
(1998) · doi:10.1002/(sici)1521-4141(199810)28:10
Cited by
Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Kümpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Jarius, S., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-023-11910-z · Cited by 258
Hofer, L. S., Ramberger, M., Gredler, V., Pescoller, A. S., Rostásy, K., Sospedra, M., Hegen, H., Berger, T., Lutterotti, A., & Reindl, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01188 · Cited by 30
Metadata
- Authors
- Zubizarreta, I., Flórez-Grau, G., Vila, G., Cabezón, R., España, C., Andorra, M., Saiz, A., Llufriu, S., Sepulveda, M., Sola-Valls, N., Martinez-Lapiscina, E. H., Pulido-Valdeolivas, I., Casanova, B., Martinez Gines, M., Tellez, N., Oreja-Guevara, C., Español, M., Trias, E., Cid, J., Juan, M., Lozano, M., Blanco, Y., Steinman, L., Benitez-Ribas, D., & Villoslada, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-04-08
- Volume
- 116
- Issue
- 17
- Pages
- 8463-8470
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2938726064
- Cited by
- 189
- References
- 46
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.